Form 13-F position report

ACORDA THERAPEUTICS INC COM PA

Reported by MORGAN STANLEY

ACORQ CUSIP 00484M700 Manager CIK 0000895421

Reported 1,176 shares, down 100 (7.8%) from the prior quarter.

Reported value 6.2%; share count -7.8% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2023
Shares 1,176 Quarter-end amount reported
Reported value $17,629 Fair value at quarter end
Consecutive quarters held 2 Through Q3 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-06-30 16600
2023-09-30 17629
2023-12-31 17745
2024-03-31 15021
2024-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

5 quarters
Quarterly reported position history for ACORDA THERAPEUTICS INC COM PA held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2024 Reduced 0 -1,137 (-100.0%) 0 $0 2024-08-14
Q1 2024 Reduced 1,137 -39 (-3.3%) < 0.01% $15,021 2024-05-15
Q4 2023 Unchanged 1,176 0 (0.0%) < 0.01% $17,745 2024-02-13
Q3 2023 Reduced 1,176 -100 (-7.8%) < 0.01% $17,629 2023-11-15
Q2 2023 New 1,276 +1,276 (0.0%) < 0.01% $16,600 2023-08-14

Who else reported the position

19 managers reported ACORDA THERAPEUTICS INC COM PA for Q3 2023.

Managers reporting ACORDA THERAPEUTICS INC COM PA in Q3 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Davidson Kempner Capital Management LP Unchanged 55,145 0 < 0.01% $749,972 2 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 46,061 +500 < 0.01% $690,000 2 qtrs
ACADIAN ASSET MANAGEMENT LLC Reduced 33,691 -440 < 0.01% $489,000 2 qtrs
VANGUARD GROUP INC New 10,734 +10,734 < 0.01% $160,903 1 qtr
BlackRock Inc Added 6,778 +2 < 0.01% $101,606 2 qtrs
WELLS FARGO & COMPANY MN Unchanged 3,740 0 < 0.01% $56,063 2 qtrs
DEUTSCHE BANK AG Unchanged 1,700 0 < 0.01% $25,483 2 qtrs
MORGAN STANLEY This report Reduced 1,176 -100 < 0.01% $17,629 2 qtrs
Russell Investments Group Ltd Unchanged 300 0 < 0.01% $4,371 2 qtrs
UBS Group AG New 134 +134 < 0.01% $2,009 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2023
Filed
November 15, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,166
Shared
0
None
10

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.